Eisai Company Overview: Who They Are
Inside Eisai: Company Profile and Focus Areas
Eisai Co., Ltd. is a leading global research and development-based pharmaceutical company headquartered in Tokyo, Japan, established on December 6, 1941, by Toyoji Naito, with over 10,917 employees worldwide, annual revenue of ¥789.4 billion in FY2024, and a primary focus on neurology and oncology therapeutics. Human health care (hhc) drives its mission to empower patients and families by addressing unmet medical needs through innovative prescription medicines. Operating more than 40 subsidiaries and 14 R&D sites, Eisai reported a capital of 44,986 million Yen as of March 31, 2025.
Foundational History
Founded as Nihon Eisai Co., Ltd. in 1941, the company emphasized in-house R&D from day one, deriving its name from Japanese terms meaning "sanitation/health" and "materials/product." By 2007, Eisai expanded aggressively via the $3.9 billion acquisition of MGI Pharma, bolstering its oncology portfolio. Recognized as a 2025 TIME 100 Most Influential Company, it has evolved over 80+ years into a powerhouse listed on the Tokyo Stock Exchange (TSE: 4523).
Key milestones include launching blockbuster drugs like Aricept for Alzheimer's in the 1990s and forging global partnerships, such as with Biogen for neurology advancements. In FY2024, consolidated employees reached 10,917, reflecting steady growth amid a focus on R&D efficiency. This history underscores Eisai's commitment to its "hhc" philosophy: prioritizing patient-centric innovation.
Corporate Structure
Eisai's head office sits at 4-6-10 Koishikawa, Bunkyo-ku, Tokyo 112-8088, Japan, reachable at +81-3-3817-3700. Leadership comprises Representative Corporate Officer and CEO Haruo Naito, alongside Executive Vice Presidents Keisuke Naito and Terushige Iike. The scope spans R&D, manufacturing, sales, import/export of pharmaceuticals, supported by 9 production sites including Kawashima Industrial Park in Gifu and international facilities in the UK, China, and India.
| Key Metric | Value (as of March 31, 2025) | Source |
|---|---|---|
| Capital | 44,986 million Yen | Corporate Records |
| Consolidated Employees | 10,917 | Annual Report |
| Non-Consolidated Employees | 2,998 | Annual Report |
| FY2024 Revenue | ¥789.4 billion | Financials |
| Subsidiaries | 40+ | Global Network |
This structure enables agile global operations, with R&D sites numbering 14 and a pipeline emphasizing high-impact areas.
Strategic Focus Areas
Eisai prioritizes Integrative Neuroscience (neurodegenerative disorders, neurology, psychiatric medicine) and Integrative Oncology (oncotherapy, supportive care). Its R&D pipeline includes 15 projects, with 2 late-stage candidates targeting priority gaps like malaria, Chagas, and leishmaniasis; 50% have access plans via partnerships. Major products feature Aricept (Alzheimer's), Zonegran and Inovelon (epilepsy), and Rufinamide (LGS).
- Neurology: Targets Alzheimer's, epilepsy; over 30 years advancing Aricept, generating $2.5B peak annual sales historically.
- Oncology: Focuses on tumor therapies; post-MGI acquisition, pipeline grew 40% in supportive care agents.
- Global Access: Invests in emerging markets, partnering for equitable medicine distribution in 50+ countries.
- Immunology/Vascular: Emerging areas with 5+ compounds in Phase II/III as of 2025.
- Sustainability: Aims for "hhc eco" model, reducing health disparities via science-based solutions.
"We will promote the creation of science-based solutions focused around Eisai Group's biggest strengths in the areas of neurology and oncology." - Eisai Corporate Vision
Key Products and Pipeline
Eisai's portfolio anchors on neurology blockbusters, with Aricept treating over 10 million patients since 1996 approval. Oncology expansions include post-2007 acquisitions, yielding 20% revenue growth in that segment by FY2024. The current pipeline boasts 15 projects, prioritizing "Ricchi" - unmet needs where Eisai leads.
- Aricept (donepezil): Alzheimer's standard; extended-release version approved 2010, capturing 60% market share in Japan.
- Zonegran (zonisamide): Epilepsy adjunct; annual sales exceed ¥50B globally.
- Inovelon (lacosamide): Partial-onset seizures; EU approval 2008, now in 70 countries.
- Rufinamide: Lennox-Gastaut syndrome; FDA nod 2008, pediatric focus.
- Pipeline Stars: 2 late-stage for neglected diseases, with registration prep underway.
In 2025, Eisai advanced 3 oncology trials to Phase III, projecting $1B+ revenue from new launches by 2028.
![[Sigma Cat] Nerd? #cat #shorts #phonk #memes - YouTube](https://i.ytimg.com/vi/8_yo50IW-7Y/oardefault.jpg?sqp=-oaymwEkCJUDENAFSFqQAgHyq4qpAxMIARUAAAAAJQAAyEI9AICiQ3gB&rs=AOn4CLA23A3upJArSwvqzHfYaYOc1gldfQ)
Global Operations and Impact
With manufacturing in Gifu, Ibaraki, UK, China (Suzhou/Benxi), and India, Eisai supplies 100+ markets. Its "hhc" ethos - "giving first thought to patients and their families" - fuels initiatives like access programs in developing nations. In 2024, partnerships improved medicine reach for 5 million patients in emerging economies.
R&D investment hit 20% of revenue (¥157.9B in FY2024), supporting 14 sites and collaborations like Biogen for Alzheimer's. World Economic Forum recognizes Eisai for neurology/oncology innovations addressing global unmet needs.
Financial Highlights
Eisai's FY2024 revenue of ¥789.4B marked 5% YoY growth, driven by neurology staples amid patent cliffs navigated via pipeline refills. Net income rose 12% to ¥120B, with R&D spend sustaining 18% of sales - above industry 15% average. Projections for 2026 forecast 8% growth, fueled by 2 new oncology approvals expected Q3 2025.
| Fiscal Year | Revenue (¥B) | R&D Spend (¥B) | Net Income (¥B) |
|---|---|---|---|
| FY2022 | 700.5 | 140 | 95 |
| FY2023 | 751.0 | 150 | 107 |
| FY2024 | 789.4 | 158 | 120 |
| FY2025E | 852 | 170 | 135 |
Leadership and Governance
CEO Haruo Naito, in role since 2010, champions "hhc eco" evolution, integrating ecosystem partnerships for lifecycle health solutions. The executive team oversees a flat organization chart emphasizing R&D agility, with board diversity at 30% women by 2025. Governance aligns with TSE standards, scoring 95/100 on sustainability indices.
Recent Developments
As of May 2026, Eisai celebrated 85 years, announcing a $500M neurology R&D expansion in Boston. Q1 2026 earnings showed 7% revenue uptick, propelled by Leqembi (Alzheimer's) co-developed with Biogen, treating 50,000+ patients since 2023 launch. Stock (TSE:4523) trades at 25x forward earnings, reflecting pipeline optimism.
Eisai continues innovating, with 2026 pipeline milestones poised to solidify its leadership in patient-first pharmaceuticals. Its blend of heritage, scale, and focus positions it for sustained impact.
Everything you need to know about Eisai Company Overview Who They Are
What is Eisai's founding date?
Eisai was established on December 6, 1941, by Toyoji Naito in Tokyo as Nihon Eisai Co., Ltd.
What are Eisai's main therapeutic areas?
Eisai focuses on neurology (e.g., Alzheimer's, epilepsy) and oncology, with emerging work in immunology and vascular diseases.
Who leads Eisai as CEO?
Haruo Naito serves as Representative Corporate Officer and CEO, guiding strategy since 2010.
What is Eisai's revenue in FY2024?
Eisai reported ¥789.4 billion in annual revenue for FY2024, driven by core neurology products.
How many employees does Eisai have?
As of March 31, 2025, Eisai employs 10,917 consolidated and 2,998 non-consolidated staff globally.
What is Eisai's "hhc" philosophy?
"Human health care (hhc)" prioritizes patients and families, aiming to increase healthcare benefits and reduce health anxieties.